This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-21-5p | ABCA1 | -0.14 | 0.92885 | -0.1 | 0.8422 | mirMAP | -0.32 | 0 | NA | |
2 | hsa-miR-21-5p | ABCA10 | -0.14 | 0.92885 | -0.77 | 0.00842 | mirMAP | -1.05 | 0 | NA | |
3 | hsa-miR-21-5p | ACAT1 | -0.14 | 0.92885 | -0.23 | 0.67804 | miRNAWalker2 validate | -0.3 | 0 | NA | |
4 | hsa-miR-21-5p | ACER3 | -0.14 | 0.92885 | 0.14 | 0.71436 | mirMAP | -0.27 | 0 | NA | |
5 | hsa-miR-21-5p | ACVR2A | -0.14 | 0.92885 | 0.08 | 0.83057 | miRNATAP | -0.23 | 0 | NA | |
6 | hsa-miR-21-5p | AKAP6 | -0.14 | 0.92885 | 0.35 | 0.12787 | MirTarget | -0.61 | 0 | NA | |
7 | hsa-miR-21-5p | AKAP9 | -0.14 | 0.92885 | -0.46 | 0.45533 | miRNAWalker2 validate | -0.17 | 0 | NA | |
8 | hsa-miR-21-5p | AKIRIN1 | -0.14 | 0.92885 | 0.45 | 0.4082 | miRNATAP | -0.11 | 0 | NA | |
9 | hsa-miR-21-5p | ANKRD46 | -0.14 | 0.92885 | -0.13 | 0.74865 | miRNAWalker2 validate; miRTarBase | -0.31 | 0 | 21219636 | Knockdown of miR-21 significantly increased the expression of ANKRD46 at both mRNA and protein levels; ANKRD46 is newly identified as a direct target of miR-21 in BC |
10 | hsa-miR-21-5p | ANKS1B | -0.14 | 0.92885 | -1.36 | 0 | MirTarget | -0.12 | 0.01421 | NA | |
11 | hsa-miR-21-5p | ANO3 | -0.14 | 0.92885 | 0.12 | 0.7608 | mirMAP | -0.87 | 0 | NA | |
12 | hsa-miR-21-5p | ANXA1 | -0.14 | 0.92885 | 1.16 | 0.09579 | MirTarget | -0.47 | 0 | NA | |
13 | hsa-miR-21-5p | APC | -0.14 | 0.92885 | -0.54 | 0.25302 | miRNAWalker2 validate | -0.25 | 0 | 23773491; 24832083 | The prognostic significance of APC gene mutation and miR 21 expression in advanced stage colorectal cancer; The aim of this study was to analyse the association of APC gene mutation and miR-21 expression with clinical outcome in CRC patients; APC gene mutation and expression of APC and miR-21 were analysed by direct DNA sequencing and real-time reverse transcription polymerase chain reaction; APC gene expression was low in CRC and negatively correlated with miR-21 expression and gene mutation; In Taiwan downregulation of the APC gene in CRC correlated with gene mutation and miR-21 upregulation; APC mutation and miR-21 expression could be used to predict the clinical outcome of CRC especially in patients with advanced disease;MicroRNA 21 promotes tumour malignancy via increased nuclear translocation of β catenin and predicts poor outcome in APC mutated but not in APC wild type colorectal cancer; However in our preliminary data the prognostic value of miR-21 levels was observed only in adenomatous polyposis coli APC-mutated tumours not in APC-wild-type tumours; We enrolled 165 colorectal tumour to determine APC mutation miR-21 levels and nuclear β-catenin expression by direct sequencing real-time PCR and immunohistochemistry |
14 | hsa-miR-21-5p | APH1B | -0.14 | 0.92885 | -1.21 | 0.00578 | MirTarget | -0.29 | 0 | NA | |
15 | hsa-miR-21-5p | APOLD1 | -0.14 | 0.92885 | -0.38 | 0.4521 | miRNAWalker2 validate | -0.52 | 0 | NA | |
16 | hsa-miR-21-5p | APPL1 | -0.14 | 0.92885 | -0.18 | 0.74888 | miRNAWalker2 validate | -0.2 | 0 | NA | |
17 | hsa-miR-21-5p | ARHGAP21 | -0.14 | 0.92885 | 0.96 | 0.09745 | miRNAWalker2 validate | -0.3 | 0 | NA | |
18 | hsa-miR-21-5p | ARHGAP24 | -0.14 | 0.92885 | -0.25 | 0.45194 | MirTarget; miRNATAP | -0.31 | 0 | NA | |
19 | hsa-miR-21-5p | ARHGEF12 | -0.14 | 0.92885 | -0.47 | 0.49356 | miRNAWalker2 validate; MirTarget | -0.24 | 0 | NA | |
20 | hsa-miR-21-5p | ARID4A | -0.14 | 0.92885 | -0.43 | 0.31434 | miRNAWalker2 validate | -0.3 | 0 | NA | |
21 | hsa-miR-21-5p | ARMC8 | -0.14 | 0.92885 | 0.15 | 0.75131 | miRNATAP | -0.11 | 0 | NA | |
22 | hsa-miR-21-5p | ARMCX1 | -0.14 | 0.92885 | -0.44 | 0.35381 | MirTarget | -0.22 | 0 | NA | |
23 | hsa-miR-21-5p | ART4 | -0.14 | 0.92885 | -0.1 | 0.80475 | mirMAP | -0.75 | 0 | NA | |
24 | hsa-miR-21-5p | ATF2 | -0.14 | 0.92885 | -0.09 | 0.80911 | miRNAWalker2 validate | -0.23 | 0 | NA | |
25 | hsa-miR-21-5p | ATM | -0.14 | 0.92885 | -0.05 | 0.92324 | mirMAP | -0.23 | 0 | 26289851 | MiR-21 is an oncomiR that is overexpressed in nearly all cancers including ATC; Hence suppression of miR-21 could pave the way for ATC therapy |
26 | hsa-miR-21-5p | ATMIN | -0.14 | 0.92885 | 0.28 | 0.62467 | miRNAWalker2 validate | -0.16 | 0 | NA | |
27 | hsa-miR-21-5p | ATP11B | -0.14 | 0.92885 | 0.92 | 0.0704 | miRNAWalker2 validate | -0.19 | 0 | NA | |
28 | hsa-miR-21-5p | ATP2B2 | -0.14 | 0.92885 | 1.34 | 1.0E-5 | mirMAP | -0.26 | 0.00043 | NA | |
29 | hsa-miR-21-5p | ATP2B4 | -0.14 | 0.92885 | 0.04 | 0.94791 | miRNAWalker2 validate; MirTarget | -0.27 | 0 | NA | |
30 | hsa-miR-21-5p | ATRN | -0.14 | 0.92885 | -0.2 | 0.73488 | miRNATAP | -0.1 | 0 | NA | |
31 | hsa-miR-21-5p | ATRX | -0.14 | 0.92885 | -0.31 | 0.60025 | miRNAWalker2 validate | -0.25 | 0 | NA | |
32 | hsa-miR-21-5p | ATXN3 | -0.14 | 0.92885 | 0.04 | 0.91739 | mirMAP | -0.17 | 0 | NA | |
33 | hsa-miR-21-5p | AUTS2 | -0.14 | 0.92885 | -0.08 | 0.88789 | miRNAWalker2 validate | -0.11 | 0.00084 | NA | |
34 | hsa-miR-21-5p | B3GNT5 | -0.14 | 0.92885 | 2.59 | 0 | miRNAWalker2 validate | -0.31 | 0 | NA | |
35 | hsa-miR-21-5p | BACE1 | -0.14 | 0.92885 | 0 | 0.99849 | mirMAP | -0.19 | 0 | NA | |
36 | hsa-miR-21-5p | BBS12 | -0.14 | 0.92885 | -0.32 | 0.20998 | MirTarget | -0.23 | 0 | NA | |
37 | hsa-miR-21-5p | BCL2 | -0.14 | 0.92885 | -1.88 | 0.00098 | miRNAWalker2 validate; miRTarBase | -0.49 | 0 | 26555418; 21468550; 25994220; 25381586; 23359184; 22964582; 21376256 | The expression of Bax Bcl-2 and miR-21 in parental and paclitaxel-resistant cells was detected by RT-PCR and Western blotting;BCL-2 up-regulation could be achieved by miR-21 overexpression which prevented T24 cells from apoptosis induced by doxorubicin; Furthermore the miR-21 induced BCL-2 up-regulation could be cancelled by the PI3K inhibitor LY294002;Meanwhile miR-21 loss reduced STAT3 and Bcl-2 activation causing an increase in the apoptosis of tumour cells in CAC mice;Changes in the sensitivity of osteosarcoma cells to CDDP were examined after transfection with miR-21 mimics or anti-miR-21 or bcl-2 siRNA in combination with CDDP;Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR 21 regulation of BCL 2 expression; We also used Western blot to measure BCL-2 protein levels after down-regulation of miR-21 expression; Besides down-regulation of miR-21 expression can inhibit BCL-2 expression in PANC-1 CFPAC-1 and MIA Paca-2 cells; Over-expression of miR-21 expression can reverse down-regulation of BCL-2 expression and apoptosis induced by resveratrol; In this study we demonstrated that the effect of resveratrol on apoptosis is due to inhibiting miR-21 regulation of BCL-2 expression;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;Bcl 2 upregulation induced by miR 21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa 2 pancreatic cancer cells; However the roles and mechanisms of miRNA miR-21 in regulation of Bcl-2 in pancreatic cancer remain to be elucidated; Then luciferase activity was observed after miR-21 mimics and pRL-TK plasmids containing wild-type and mutant 3'UTRs of Bcl-2 mRNA were co-transfected; Cells transfected with miR-21 inhibitor revealed an opposite trend. There was a significant increase in luciferase activity in the cells transfected with the wild-type pRL-TK plasmid in contrast to those transfected with the mutant one indicating that miR-21 promotes Bcl-2 expression by binding directly to the 3'UTR of Bcl-2 mRNA; Upregulation of Bcl-2 directly induced by miR-21 is associated with apoptosis chemoresistance and proliferation of MIA PaCa-2 pancreatic cancer cells |
38 | hsa-miR-21-5p | BCL6 | -0.14 | 0.92885 | 0.04 | 0.94311 | miRNAWalker2 validate | -0.3 | 0 | NA | |
39 | hsa-miR-21-5p | BDH2 | -0.14 | 0.92885 | 0.01 | 0.98164 | miRNAWalker2 validate | -0.19 | 0 | NA | |
40 | hsa-miR-21-5p | BMP2K | -0.14 | 0.92885 | -0.11 | 0.76209 | mirMAP | -0.2 | 0 | NA | |
41 | hsa-miR-21-5p | BMP3 | -0.14 | 0.92885 | 0.12 | 0.7655 | MirTarget | -1 | 0 | NA | |
42 | hsa-miR-21-5p | BMPR2 | -0.14 | 0.92885 | -0.23 | 0.71375 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.22 | 0 | NA | |
43 | hsa-miR-21-5p | BOC | -0.14 | 0.92885 | 1.09 | 0.02665 | miRNAWalker2 validate | -0.37 | 0 | NA | |
44 | hsa-miR-21-5p | BTBD3 | -0.14 | 0.92885 | 0.82 | 0.093 | miRNAWalker2 validate; miRNATAP | -0.13 | 0 | NA | |
45 | hsa-miR-21-5p | BTBD7 | -0.14 | 0.92885 | -0.2 | 0.68059 | miRNAWalker2 validate | -0.24 | 0 | NA | |
46 | hsa-miR-21-5p | BTG2 | -0.14 | 0.92885 | -1.49 | 0.04452 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.27 | 0 | 24821435 | miR 21 regulates N methyl N nitro N' nitrosoguanidine induced gastric tumorigenesis by targeting FASLG and BTG2 |
47 | hsa-miR-21-5p | C16orf52 | -0.14 | 0.92885 | -0.43 | 0.24716 | miRNATAP | -0.17 | 0 | NA | |
48 | hsa-miR-21-5p | C1orf226 | -0.14 | 0.92885 | -0.84 | 0.08628 | mirMAP | -0.21 | 6.0E-5 | NA | |
49 | hsa-miR-21-5p | CADM2 | -0.14 | 0.92885 | -2.36 | 0 | mirMAP; miRNATAP | -0.85 | 0 | NA | |
50 | hsa-miR-21-5p | CALD1 | -0.14 | 0.92885 | 0.44 | 0.55518 | miRNAWalker2 validate; MirTarget | -0.11 | 0.00046 | NA | |
51 | hsa-miR-21-5p | CALN1 | -0.14 | 0.92885 | -1.14 | 0.00178 | mirMAP | -0.5 | 0 | NA | |
52 | hsa-miR-21-5p | CASC4 | -0.14 | 0.92885 | -0.61 | 0.33534 | miRNATAP | -0.1 | 1.0E-5 | NA | |
53 | hsa-miR-21-5p | CASP10 | -0.14 | 0.92885 | 0.35 | 0.2959 | mirMAP | -0.18 | 0 | NA | |
54 | hsa-miR-21-5p | CBL | -0.14 | 0.92885 | 0.4 | 0.40307 | mirMAP | -0.22 | 0 | NA | |
55 | hsa-miR-21-5p | CCDC121 | -0.14 | 0.92885 | -0.15 | 0.51559 | MirTarget | -0.27 | 0 | NA | |
56 | hsa-miR-21-5p | CCDC152 | -0.14 | 0.92885 | -0.86 | 0.00017 | mirMAP | -0.36 | 0 | NA | |
57 | hsa-miR-21-5p | CCNG1 | -0.14 | 0.92885 | -0.41 | 0.48628 | miRNAWalker2 validate | -0.35 | 0 | NA | |
58 | hsa-miR-21-5p | CCNG2 | -0.14 | 0.92885 | -1.09 | 0.07868 | mirMAP | -0.1 | 0.00147 | NA | |
59 | hsa-miR-21-5p | CDK6 | -0.14 | 0.92885 | 1.59 | 0.00053 | miRNAWalker2 validate; mirMAP | -0.2 | 3.0E-5 | NA | |
60 | hsa-miR-21-5p | CEP152 | -0.14 | 0.92885 | 0.71 | 0.00105 | miRNAWalker2 validate | -0.12 | 3.0E-5 | NA | |
61 | hsa-miR-21-5p | CEP68 | -0.14 | 0.92885 | -0.25 | 0.61417 | miRNATAP | -0.39 | 0 | NA | |
62 | hsa-miR-21-5p | CEP97 | -0.14 | 0.92885 | -0.22 | 0.39384 | miRNAWalker2 validate; MirTarget | -0.1 | 0.00272 | NA | |
63 | hsa-miR-21-5p | CLDN8 | -0.14 | 0.92885 | 0.66 | 0.11205 | MirTarget | -0.38 | 9.0E-5 | NA | |
64 | hsa-miR-21-5p | CLIC2 | -0.14 | 0.92885 | 0.3 | 0.41937 | MirTarget | -0.3 | 0 | NA | |
65 | hsa-miR-21-5p | CLIP4 | -0.14 | 0.92885 | 1.12 | 0.00734 | miRNAWalker2 validate | -0.48 | 0 | NA | |
66 | hsa-miR-21-5p | CLOCK | -0.14 | 0.92885 | -0.11 | 0.76002 | miRNAWalker2 validate | -0.24 | 0 | NA | |
67 | hsa-miR-21-5p | CNTFR | -0.14 | 0.92885 | 0.59 | 0.14799 | miRNATAP | -1.13 | 0 | NA | |
68 | hsa-miR-21-5p | COBLL1 | -0.14 | 0.92885 | -0.23 | 0.62011 | miRNAWalker2 validate | -0.4 | 0 | NA | |
69 | hsa-miR-21-5p | CPEB3 | -0.14 | 0.92885 | -0.86 | 0.00232 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.34 | 0 | NA | |
70 | hsa-miR-21-5p | CREBL2 | -0.14 | 0.92885 | -0.55 | 0.34569 | miRNATAP | -0.28 | 0 | NA | |
71 | hsa-miR-21-5p | CRIM1 | -0.14 | 0.92885 | -0.31 | 0.6343 | miRNATAP | -0.6 | 0 | NA | |
72 | hsa-miR-21-5p | CRTC3 | -0.14 | 0.92885 | -0.19 | 0.72029 | mirMAP | -0.11 | 0 | NA | |
73 | hsa-miR-21-5p | CSRNP3 | -0.14 | 0.92885 | -0.3 | 0.37119 | miRNATAP | -0.73 | 0 | NA | |
74 | hsa-miR-21-5p | CXXC4 | -0.14 | 0.92885 | -1.31 | 0 | mirMAP | -0.26 | 3.0E-5 | NA | |
75 | hsa-miR-21-5p | CYBRD1 | -0.14 | 0.92885 | -1.33 | 0.0758 | miRNAWalker2 validate | -0.53 | 0 | NA | |
76 | hsa-miR-21-5p | CYP4V2 | -0.14 | 0.92885 | -0.47 | 0.30448 | miRNAWalker2 validate | -0.22 | 0 | NA | |
77 | hsa-miR-21-5p | DAAM1 | -0.14 | 0.92885 | -0.43 | 0.32793 | miRNAWalker2 validate | -0.28 | 0 | NA | |
78 | hsa-miR-21-5p | DCP1A | -0.14 | 0.92885 | -0.13 | 0.77497 | miRNAWalker2 validate | -0.27 | 0 | NA | |
79 | hsa-miR-21-5p | DDHD2 | -0.14 | 0.92885 | -0 | 0.9934 | miRNAWalker2 validate | -0.27 | 0 | NA | |
80 | hsa-miR-21-5p | DDR2 | -0.14 | 0.92885 | 0.43 | 0.24643 | miRNAWalker2 validate | -0.62 | 0 | NA | |
81 | hsa-miR-21-5p | DDX3X | -0.14 | 0.92885 | 0 | 0.99521 | miRNAWalker2 validate | -0.2 | 0 | NA | |
82 | hsa-miR-21-5p | DLG1 | -0.14 | 0.92885 | 0.14 | 0.79636 | miRNAWalker2 validate | -0.15 | 0 | NA | |
83 | hsa-miR-21-5p | DLGAP1 | -0.14 | 0.92885 | 0.53 | 0.1247 | miRNATAP | -0.28 | 0.00212 | NA | |
84 | hsa-miR-21-5p | DMD | -0.14 | 0.92885 | 1.62 | 0.00016 | miRNAWalker2 validate | -0.92 | 0 | NA | |
85 | hsa-miR-21-5p | DMTF1 | -0.14 | 0.92885 | 0.08 | 0.86606 | miRNAWalker2 validate | -0.12 | 0 | NA | |
86 | hsa-miR-21-5p | DOCK4 | -0.14 | 0.92885 | 0.07 | 0.86467 | miRNAWalker2 validate; miRTarBase | -0.22 | 0 | NA | |
87 | hsa-miR-21-5p | DOCK7 | -0.14 | 0.92885 | 0.71 | 0.15566 | miRNAWalker2 validate; miRTarBase | -0.22 | 0 | NA | |
88 | hsa-miR-21-5p | DSE | -0.14 | 0.92885 | 0.16 | 0.74414 | miRNAWalker2 validate | -0.11 | 6.0E-5 | NA | |
89 | hsa-miR-21-5p | DST | -0.14 | 0.92885 | 0.02 | 0.98236 | mirMAP | -0.66 | 0 | 22403704 | While the EDCs and estrogen similarly altered the expression of multiple microRNAs in MCF-7 cells including miR-21 differential patterns of microRNA expression were induced by DDT and BPA compared to estrogen |
90 | hsa-miR-21-5p | DYNC1LI2 | -0.14 | 0.92885 | 0.17 | 0.78813 | miRNAWalker2 validate | -0.19 | 0 | NA | |
91 | hsa-miR-21-5p | EGFR | -0.14 | 0.92885 | 2.45 | 0 | miRNAWalker2 validate; miRTarBase | -0.67 | 0 | 24198203; 20113523; 24012640; 24331411; 26563758; 19597153; 26026961; 20048743 | In radically resected NSCLC patients the expression levels of miR-21 10b in patients with EGFR mutation were much higher than those without mutation;Thus the miR-21 inhibitor might interrupt the activity of EGFR pathways independently of PTEN status;Further the expression of miR-21 is regulated by EGFR via the activation of β-catenin and AP-1; These data indicate that a feedback loop exists between miR-21 and EGFR; These results clarify a novel association between miR-21 and EGFR in the regulation of cancer cell progression;MiR 21 overexpression is associated with acquired resistance of EGFR TKI in non small cell lung cancer;Higher expression levels of miR-21 AmiR-27a and miR-218 detected in this study suggest potential roles of these miRNAs in primary resistance to EGFR-TKI in advanced NSCLC patients with EGFR exon 19 deletion mutations;MiR 21 is an EGFR regulated anti apoptotic factor in lung cancer in never smokers; The changes in expression of some of these miRNAs including miR-21 were more remarkable in cases with EGFR mutations than in those without these mutations; In the never-smoker-derived lung adenocarcinoma cell line H3255 with mutant EGFR and high levels of p-EGFR and miR-21 antisense inhibition of miR-21 enhanced AG1478-induced apoptosis; In a never-smoker-derived adenocarcinoma cell line H441 with wild-type EGFR the antisense miR-21 not only showed the additive effect with AG1478 but also induced apoptosis by itself; These results suggest that aberrantly increased expression of miR-21 which is enhanced further by the activated EGFR signaling pathway plays a significant role in lung carcinogenesis in never-smokers as well as in smokers and is a potential therapeutic target in both EGFR-mutant and wild-type cases;Nickel may contribute to EGFR mutation and synergistically promotes tumor invasion in EGFR mutated lung cancer via nickel induced microRNA 21 expression;Downregulation of miR 21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status |
92 | hsa-miR-21-5p | EIF1AX | -0.14 | 0.92885 | -0.01 | 0.9895 | miRNATAP | -0.17 | 0 | NA | |
93 | hsa-miR-21-5p | EIF4A2 | -0.14 | 0.92885 | -0.08 | 0.91716 | miRNAWalker2 validate; miRTarBase | -0.22 | 0 | NA | |
94 | hsa-miR-21-5p | EIF4EBP2 | -0.14 | 0.92885 | 0.1 | 0.88305 | miRNAWalker2 validate | -0.35 | 0 | NA | |
95 | hsa-miR-21-5p | EIF5 | -0.14 | 0.92885 | -0.15 | 0.82782 | miRNAWalker2 validate | -0.14 | 0 | NA | |
96 | hsa-miR-21-5p | ELF2 | -0.14 | 0.92885 | -0.15 | 0.74935 | MirTarget; miRNATAP | -0.17 | 0 | NA | |
97 | hsa-miR-21-5p | ELOVL7 | -0.14 | 0.92885 | 1 | 0.00242 | miRNAWalker2 validate | -0.24 | 0 | NA | |
98 | hsa-miR-21-5p | EPHA4 | -0.14 | 0.92885 | 0.31 | 0.35598 | miRNAWalker2 validate; miRNATAP | -0.4 | 0 | NA | |
99 | hsa-miR-21-5p | EPM2A | -0.14 | 0.92885 | 0.17 | 0.54145 | miRNAWalker2 validate | -0.37 | 0 | NA | |
100 | hsa-miR-21-5p | EPM2AIP1 | -0.14 | 0.92885 | -0.56 | 0.27055 | mirMAP | -0.2 | 0 | NA | |
101 | hsa-miR-21-5p | ESYT2 | -0.14 | 0.92885 | 0.43 | 0.52514 | miRNAWalker2 validate; MirTarget | -0.17 | 0 | NA | |
102 | hsa-miR-21-5p | EXOC5 | -0.14 | 0.92885 | 0.03 | 0.9537 | miRNAWalker2 validate | -0.14 | 0 | NA | |
103 | hsa-miR-21-5p | FAM107B | -0.14 | 0.92885 | -0.16 | 0.79198 | miRNATAP | -0.11 | 0.00019 | NA | |
104 | hsa-miR-21-5p | FAM126B | -0.14 | 0.92885 | 0.11 | 0.78029 | miRNAWalker2 validate | -0.22 | 0 | NA | |
105 | hsa-miR-21-5p | FAM20B | -0.14 | 0.92885 | -0 | 0.9953 | miRNAWalker2 validate | -0.1 | 0 | NA | |
106 | hsa-miR-21-5p | FAM46A | -0.14 | 0.92885 | 0.38 | 0.41443 | miRNAWalker2 validate; miRNATAP | -0.21 | 0 | NA | |
107 | hsa-miR-21-5p | FAM63B | -0.14 | 0.92885 | -0.74 | 0.01954 | miRNATAP | -0.35 | 0 | NA | |
108 | hsa-miR-21-5p | FBXL17 | -0.14 | 0.92885 | -0.92 | 0.04247 | miRNAWalker2 validate; miRNATAP | -0.29 | 0 | NA | |
109 | hsa-miR-21-5p | FBXO11 | -0.14 | 0.92885 | 0.22 | 0.69545 | miRNAWalker2 validate; miRNATAP | -0.15 | 0 | NA | |
110 | hsa-miR-21-5p | FBXO3 | -0.14 | 0.92885 | -0.38 | 0.42437 | miRNAWalker2 validate | -0.16 | 0 | NA | |
111 | hsa-miR-21-5p | FCHO2 | -0.14 | 0.92885 | -0.61 | 0.19755 | miRNATAP | -0.21 | 0 | NA | |
112 | hsa-miR-21-5p | FERMT2 | -0.14 | 0.92885 | 0.06 | 0.91492 | miRNAWalker2 validate | -0.4 | 0 | NA | |
113 | hsa-miR-21-5p | FGD4 | -0.14 | 0.92885 | 0.32 | 0.39156 | MirTarget | -0.46 | 0 | NA | |
114 | hsa-miR-21-5p | FGF1 | -0.14 | 0.92885 | -0.65 | 0.10119 | MirTarget | -0.37 | 0 | NA | |
115 | hsa-miR-21-5p | FGF2 | -0.14 | 0.92885 | 0.64 | 0.10706 | mirMAP | -1 | 0 | NA | |
116 | hsa-miR-21-5p | FIGN | -0.14 | 0.92885 | 1.66 | 0 | miRNAWalker2 validate | -0.63 | 0 | NA | |
117 | hsa-miR-21-5p | FILIP1L | -0.14 | 0.92885 | -0.43 | 0.38861 | miRNAWalker2 validate | -0.24 | 0 | NA | |
118 | hsa-miR-21-5p | FKBP5 | -0.14 | 0.92885 | 0.48 | 0.42817 | miRNAWalker2 validate | -0.19 | 0.00017 | NA | |
119 | hsa-miR-21-5p | FMN1 | -0.14 | 0.92885 | -1.29 | 0 | miRNATAP | -0.16 | 0.01106 | NA | |
120 | hsa-miR-21-5p | FMOD | -0.14 | 0.92885 | -1.02 | 0.12251 | miRNAWalker2 validate; miRTarBase | -0.39 | 0 | 23445447; 19906824 | Our method exhibits ultrahigh sensitivity toward miR-21 with detection limits of 10 fM at 37 °C and 1 aM at 4 °C which corresponds to nine strands of miR-21 in a 15 μL sample and it is capable of distinguishing among miRNA family members;Gain-of miR-21 function in MSMC and LSMC reduced TGF-beta-induced expression of fibromodulin and TGF-beta-induced factor P < 0.05 and moderately altered the rate of cell growth and caspase-3/7 activity in these cells |
121 | hsa-miR-21-5p | FOXN3 | -0.14 | 0.92885 | 0.22 | 0.69194 | miRNAWalker2 validate; mirMAP | -0.37 | 0 | NA | |
122 | hsa-miR-21-5p | FOXP2 | -0.14 | 0.92885 | -0.31 | 0.28517 | mirMAP | -0.7 | 0 | NA | |
123 | hsa-miR-21-5p | FREM2 | -0.14 | 0.92885 | 1.55 | 8.0E-5 | mirMAP | -0.3 | 0.00441 | NA | |
124 | hsa-miR-21-5p | FRMD3 | -0.14 | 0.92885 | 1.47 | 0 | MirTarget | -0.85 | 0 | NA | |
125 | hsa-miR-21-5p | FZD4 | -0.14 | 0.92885 | -0.76 | 0.18617 | mirMAP | -0.62 | 0 | NA | |
126 | hsa-miR-21-5p | GALNT12 | -0.14 | 0.92885 | 0.97 | 7.0E-5 | MirTarget | -0.16 | 0.00161 | NA | |
127 | hsa-miR-21-5p | GFOD1 | -0.14 | 0.92885 | 0.83 | 2.0E-5 | mirMAP | -0.24 | 0 | NA | |
128 | hsa-miR-21-5p | GFPT1 | -0.14 | 0.92885 | 0.17 | 0.79739 | mirMAP | -0.14 | 0 | NA | |
129 | hsa-miR-21-5p | GLCCI1 | -0.14 | 0.92885 | -1.02 | 0.01247 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.14 | 2.0E-5 | NA | |
130 | hsa-miR-21-5p | GLG1 | -0.14 | 0.92885 | 0.46 | 0.51464 | miRNAWalker2 validate | -0.1 | 0 | NA | |
131 | hsa-miR-21-5p | GNAQ | -0.14 | 0.92885 | -0.39 | 0.50275 | miRNAWalker2 validate | -0.25 | 0 | NA | |
132 | hsa-miR-21-5p | GNE | -0.14 | 0.92885 | 0.33 | 0.47681 | miRNAWalker2 validate | -0.36 | 0 | NA | |
133 | hsa-miR-21-5p | GNG2 | -0.14 | 0.92885 | 0 | 0.99098 | miRNATAP | -0.41 | 0 | NA | |
134 | hsa-miR-21-5p | GOLGA4 | -0.14 | 0.92885 | -0.11 | 0.86419 | miRNAWalker2 validate | -0.22 | 0 | NA | |
135 | hsa-miR-21-5p | GPAM | -0.14 | 0.92885 | -0.43 | 0.40771 | miRNAWalker2 validate; mirMAP | -1 | 0 | NA | |
136 | hsa-miR-21-5p | GPD1L | -0.14 | 0.92885 | -1.55 | 0.00697 | miRNAWalker2 validate | -0.34 | 0 | NA | |
137 | hsa-miR-21-5p | GRAMD3 | -0.14 | 0.92885 | 0.58 | 0.20354 | MirTarget | -0.19 | 0 | NA | |
138 | hsa-miR-21-5p | GRIK3 | -0.14 | 0.92885 | -3.91 | 0 | mirMAP | -0.3 | 0.00129 | NA | |
139 | hsa-miR-21-5p | GTF2A1 | -0.14 | 0.92885 | -0.31 | 0.27739 | miRNAWalker2 validate | -0.28 | 0 | NA | |
140 | hsa-miR-21-5p | GTF2I | -0.14 | 0.92885 | 0.09 | 0.89098 | miRNAWalker2 validate | -0.22 | 0 | NA | |
141 | hsa-miR-21-5p | GXYLT1 | -0.14 | 0.92885 | -0.17 | 0.68744 | mirMAP | -0.12 | 0 | NA | |
142 | hsa-miR-21-5p | HBP1 | -0.14 | 0.92885 | -0.3 | 0.63076 | miRNATAP | -0.26 | 0 | 26282675 | MicroRNA 21 is a potential link between non alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1 p53 Srebp1c pathway; Further studies revealed that Hbp1 was a novel target of microRNA-21 and a transcriptional activator of p53 |
143 | hsa-miR-21-5p | HECTD1 | -0.14 | 0.92885 | -0.24 | 0.71629 | miRNAWalker2 validate | -0.22 | 0 | NA | |
144 | hsa-miR-21-5p | HERPUD2 | -0.14 | 0.92885 | -0.03 | 0.94786 | miRNAWalker2 validate | -0.11 | 0 | NA | |
145 | hsa-miR-21-5p | HIPK1 | -0.14 | 0.92885 | -0.24 | 0.68365 | mirMAP | -0.2 | 0 | NA | |
146 | hsa-miR-21-5p | HIPK3 | -0.14 | 0.92885 | -0.2 | 0.68645 | MirTarget | -0.52 | 0 | NA | |
147 | hsa-miR-21-5p | HIVEP3 | -0.14 | 0.92885 | -0.17 | 0.66422 | mirMAP | -0.13 | 0 | NA | |
148 | hsa-miR-21-5p | HOXA9 | -0.14 | 0.92885 | 0.3 | 0.24005 | miRNAWalker2 validate | -0.5 | 0 | NA | |
149 | hsa-miR-21-5p | HPS5 | -0.14 | 0.92885 | 0.26 | 0.56019 | miRNAWalker2 validate | -0.23 | 0 | NA | |
150 | hsa-miR-21-5p | HSD17B4 | -0.14 | 0.92885 | -1.11 | 0.07508 | MirTarget | -0.16 | 0 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 91 | 1784 | 1.529e-13 | 7.115e-10 |
2 | POSITIVE REGULATION OF GENE EXPRESSION | 84 | 1733 | 2.346e-11 | 5.457e-08 |
3 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 81 | 1672 | 5.922e-11 | 9.184e-08 |
4 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 84 | 1805 | 1.821e-10 | 2.119e-07 |
5 | REGULATION OF CELL DIFFERENTIATION | 73 | 1492 | 4.048e-10 | 3.767e-07 |
6 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 56 | 1004 | 5.699e-10 | 4.42e-07 |
7 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 44 | 689 | 8.05e-10 | 5.351e-07 |
8 | REGULATION OF CELL PROLIFERATION | 72 | 1496 | 1.115e-09 | 6.487e-07 |
9 | PROTEIN PHOSPHORYLATION | 53 | 944 | 1.375e-09 | 7.109e-07 |
10 | CELL DEVELOPMENT | 68 | 1426 | 5.076e-09 | 2.147e-06 |
11 | TISSUE DEVELOPMENT | 71 | 1518 | 4.94e-09 | 2.147e-06 |
12 | RESPONSE TO ENDOGENOUS STIMULUS | 68 | 1450 | 9.905e-09 | 3.841e-06 |
13 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 74 | 1656 | 1.536e-08 | 5.106e-06 |
14 | NEUROGENESIS | 66 | 1402 | 1.458e-08 | 5.106e-06 |
15 | INTRACELLULAR SIGNAL TRANSDUCTION | 70 | 1572 | 4.626e-08 | 1.266e-05 |
16 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 44 | 788 | 4.48e-08 | 1.266e-05 |
17 | CIRCULATORY SYSTEM DEVELOPMENT | 44 | 788 | 4.48e-08 | 1.266e-05 |
18 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 21 | 229 | 7.227e-08 | 1.868e-05 |
19 | ORGAN MORPHOGENESIS | 45 | 841 | 1.074e-07 | 2.547e-05 |
20 | PHOSPHORYLATION | 58 | 1228 | 1.095e-07 | 2.547e-05 |
21 | POSITIVE REGULATION OF GROWTH | 21 | 238 | 1.395e-07 | 3.091e-05 |
22 | EPITHELIUM DEVELOPMENT | 48 | 945 | 1.871e-07 | 3.537e-05 |
23 | KIDNEY EPITHELIUM DEVELOPMENT | 15 | 125 | 1.703e-07 | 3.537e-05 |
24 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 23 | 285 | 1.803e-07 | 3.537e-05 |
25 | RENAL TUBULE DEVELOPMENT | 12 | 78 | 1.901e-07 | 3.537e-05 |
26 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 50 | 1008 | 2.097e-07 | 3.753e-05 |
27 | REGULATION OF DEVELOPMENTAL GROWTH | 23 | 289 | 2.314e-07 | 3.987e-05 |
28 | REGULATION OF PROTEIN MODIFICATION PROCESS | 72 | 1710 | 2.596e-07 | 4.314e-05 |
29 | POSITIVE REGULATION OF CELL PROLIFERATION | 43 | 814 | 2.973e-07 | 4.627e-05 |
30 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 50 | 1021 | 3.082e-07 | 4.627e-05 |
31 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 54 | 1142 | 3.035e-07 | 4.627e-05 |
32 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 42 | 799 | 4.688e-07 | 6.817e-05 |
33 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 31 | 498 | 4.899e-07 | 6.908e-05 |
34 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 79 | 1977 | 5.176e-07 | 7.083e-05 |
35 | POSITIVE REGULATION OF DEVELOPMENTAL GROWTH | 16 | 156 | 5.855e-07 | 7.583e-05 |
36 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 35 | 609 | 5.867e-07 | 7.583e-05 |
37 | NEGATIVE REGULATION OF CELL PROLIFERATION | 36 | 643 | 7.485e-07 | 9.413e-05 |
38 | GROWTH | 27 | 410 | 9.283e-07 | 0.0001123 |
39 | REGULATION OF CELL DEATH | 63 | 1472 | 9.413e-07 | 0.0001123 |
40 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 60 | 1381 | 1.087e-06 | 0.0001264 |
41 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 39 | 740 | 1.152e-06 | 0.0001308 |
42 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 64 | 1517 | 1.244e-06 | 0.0001378 |
43 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 41 | 801 | 1.274e-06 | 0.0001378 |
44 | NEPHRON EPITHELIUM DEVELOPMENT | 12 | 93 | 1.339e-06 | 0.0001416 |
45 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 29 | 470 | 1.376e-06 | 0.0001423 |
46 | TUBE DEVELOPMENT | 32 | 552 | 1.504e-06 | 0.0001521 |
47 | UROGENITAL SYSTEM DEVELOPMENT | 22 | 299 | 1.585e-06 | 0.000157 |
48 | CELLULAR COMPONENT MORPHOGENESIS | 44 | 900 | 1.735e-06 | 0.0001682 |
49 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 43 | 872 | 1.835e-06 | 0.0001742 |
50 | PROTEIN LOCALIZATION | 72 | 1805 | 1.938e-06 | 0.0001803 |
51 | SMOOTH MUSCLE TISSUE DEVELOPMENT | 6 | 18 | 2e-06 | 0.0001824 |
52 | MESONEPHRIC TUBULE MORPHOGENESIS | 9 | 53 | 2.8e-06 | 0.0002459 |
53 | HEAD DEVELOPMENT | 37 | 709 | 2.751e-06 | 0.0002459 |
54 | REGULATION OF OSSIFICATION | 16 | 178 | 3.385e-06 | 0.0002916 |
55 | REGULATION OF GROWTH | 34 | 633 | 3.805e-06 | 0.0003219 |
56 | VASCULATURE DEVELOPMENT | 28 | 469 | 3.941e-06 | 0.0003274 |
57 | CELL PROJECTION ORGANIZATION | 43 | 902 | 4.338e-06 | 0.000348 |
58 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 49 | 1087 | 4.273e-06 | 0.000348 |
59 | MUSCLE TISSUE DEVELOPMENT | 20 | 275 | 5.617e-06 | 0.0004356 |
60 | TUBE MORPHOGENESIS | 22 | 323 | 5.565e-06 | 0.0004356 |
61 | TISSUE MORPHOGENESIS | 30 | 533 | 5.767e-06 | 0.0004399 |
62 | REGULATION OF ORGAN GROWTH | 10 | 73 | 5.919e-06 | 0.0004442 |
63 | NEGATIVE REGULATION OF GENE EXPRESSION | 61 | 1493 | 6.298e-06 | 0.0004454 |
64 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 61 | 1492 | 6.168e-06 | 0.0004454 |
65 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 57 | 1360 | 6.198e-06 | 0.0004454 |
66 | MESONEPHROS DEVELOPMENT | 11 | 90 | 6.317e-06 | 0.0004454 |
67 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 45 | 983 | 7.315e-06 | 0.000508 |
68 | NEURON DEVELOPMENT | 35 | 687 | 8.672e-06 | 0.000583 |
69 | REGULATION OF KINASE ACTIVITY | 38 | 776 | 8.771e-06 | 0.000583 |
70 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 71 | 1848 | 8.526e-06 | 0.000583 |
71 | PROTEIN AUTOPHOSPHORYLATION | 16 | 192 | 8.95e-06 | 0.0005834 |
72 | DEVELOPMENTAL GROWTH | 22 | 333 | 9.027e-06 | 0.0005834 |
73 | NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 26 | 437 | 9.276e-06 | 0.0005913 |
74 | HEART DEVELOPMENT | 27 | 466 | 1.01e-05 | 0.0006353 |
75 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 64 | 1618 | 1.024e-05 | 0.0006356 |
76 | NEURON DIFFERENTIATION | 41 | 874 | 1.073e-05 | 0.0006571 |
77 | NEGATIVE REGULATION OF CELL COMMUNICATION | 51 | 1192 | 1.145e-05 | 0.0006919 |
78 | NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 12 | 115 | 1.262e-05 | 0.000743 |
79 | NEPHRON DEVELOPMENT | 12 | 115 | 1.262e-05 | 0.000743 |
80 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 57 | 1395 | 1.308e-05 | 0.0007608 |
81 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 49 | 1135 | 1.361e-05 | 0.0007816 |
82 | REGULATION OF TRANSFERASE ACTIVITY | 43 | 946 | 1.401e-05 | 0.0007919 |
83 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 39 | 823 | 1.413e-05 | 0.0007919 |
84 | REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 12 | 118 | 1.641e-05 | 0.0009091 |
85 | MORPHOGENESIS OF AN EPITHELIUM | 24 | 400 | 1.781e-05 | 0.0009752 |
86 | POSITIVE REGULATION OF OSSIFICATION | 10 | 84 | 2.104e-05 | 0.001139 |
87 | NEGATIVE REGULATION OF CELL CYCLE | 25 | 433 | 2.279e-05 | 0.001214 |
88 | BEHAVIOR | 28 | 516 | 2.296e-05 | 0.001214 |
89 | NEURON PROJECTION DEVELOPMENT | 29 | 545 | 2.356e-05 | 0.001232 |
90 | FORELIMB MORPHOGENESIS | 7 | 40 | 2.974e-05 | 0.001521 |
91 | DEFINITIVE HEMOPOIESIS | 5 | 17 | 2.974e-05 | 0.001521 |
92 | POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 10 | 88 | 3.172e-05 | 0.001604 |
93 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 31 | 616 | 3.599e-05 | 0.001801 |
94 | RESPONSE TO NITROGEN COMPOUND | 39 | 859 | 3.658e-05 | 0.001811 |
95 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 42 | 957 | 3.993e-05 | 0.001956 |
96 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 36 | 771 | 4.139e-05 | 0.002006 |
97 | NEGATIVE REGULATION OF PHOSPHORYLATION | 24 | 422 | 4.214e-05 | 0.002022 |
98 | RESPONSE TO ABIOTIC STIMULUS | 44 | 1024 | 4.286e-05 | 0.002035 |
99 | RESPONSE TO ACID CHEMICAL | 20 | 319 | 4.815e-05 | 0.00224 |
100 | REGULATION OF MAP KINASE ACTIVITY | 20 | 319 | 4.815e-05 | 0.00224 |
101 | CELLULAR RESPONSE TO ACID CHEMICAL | 14 | 175 | 5.066e-05 | 0.002298 |
102 | NEGATIVE REGULATION OF CELL DEATH | 39 | 872 | 5.066e-05 | 0.002298 |
103 | REGULATION OF OSTEOBLAST DIFFERENTIATION | 11 | 112 | 5.088e-05 | 0.002298 |
104 | REGULATION OF TRANSPORTER ACTIVITY | 15 | 198 | 5.173e-05 | 0.002315 |
105 | CELL CYCLE ARREST | 13 | 154 | 5.378e-05 | 0.002377 |
106 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 27 | 513 | 5.415e-05 | 0.002377 |
107 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 44 | 1036 | 5.622e-05 | 0.002412 |
108 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 44 | 1036 | 5.622e-05 | 0.002412 |
109 | BRANCHING INVOLVED IN URETERIC BUD MORPHOGENESIS | 7 | 44 | 5.651e-05 | 0.002412 |
110 | POSITIVE REGULATION OF OSTEOBLAST DIFFERENTIATION | 8 | 60 | 6.216e-05 | 0.002629 |
111 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 66 | 1791 | 6.66e-05 | 0.002792 |
112 | MUSCLE ORGAN DEVELOPMENT | 18 | 277 | 7.224e-05 | 0.002975 |
113 | SENSORY ORGAN DEVELOPMENT | 26 | 493 | 7.184e-05 | 0.002975 |
114 | DENDRITE DEVELOPMENT | 9 | 79 | 7.709e-05 | 0.003146 |
115 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 47 | 1152 | 8.225e-05 | 0.003328 |
116 | REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 15 | 207 | 8.571e-05 | 0.003438 |
117 | METANEPHROS DEVELOPMENT | 9 | 81 | 9.387e-05 | 0.003733 |
118 | REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORT | 7 | 48 | 0.0001004 | 0.003958 |
119 | RESPONSE TO GROWTH FACTOR | 25 | 475 | 0.0001018 | 0.003982 |
120 | KIDNEY MORPHOGENESIS | 9 | 82 | 0.0001034 | 0.004008 |
121 | PLATELET DERIVED GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 6 | 34 | 0.0001063 | 0.004055 |
122 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 26 | 505 | 0.0001061 | 0.004055 |
123 | CELLULAR MACROMOLECULE LOCALIZATION | 49 | 1234 | 0.0001116 | 0.004223 |
124 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 18 | 289 | 0.0001237 | 0.004567 |
125 | EMBRYONIC MORPHOGENESIS | 27 | 539 | 0.0001233 | 0.004567 |
126 | TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 14 | 190 | 0.0001228 | 0.004567 |
127 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 27 | 541 | 0.000131 | 0.004763 |
128 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 27 | 541 | 0.000131 | 0.004763 |
129 | DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS | 10 | 104 | 0.0001327 | 0.004788 |
130 | SKELETAL SYSTEM DEVELOPMENT | 24 | 455 | 0.0001351 | 0.004834 |
131 | PALATE DEVELOPMENT | 9 | 85 | 0.0001367 | 0.004854 |
132 | APPENDAGE DEVELOPMENT | 13 | 169 | 0.0001387 | 0.004854 |
133 | LIMB DEVELOPMENT | 13 | 169 | 0.0001387 | 0.004854 |
134 | NEGATIVE REGULATION OF ERK1 AND ERK2 CASCADE | 7 | 52 | 0.0001686 | 0.005856 |
135 | MYOBLAST DIFFERENTIATION | 6 | 37 | 0.0001735 | 0.005979 |
136 | RESPONSE TO HORMONE | 38 | 893 | 0.0001758 | 0.006014 |
137 | IMMUNE SYSTEM DEVELOPMENT | 28 | 582 | 0.000182 | 0.00618 |
138 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 68 | 1929 | 0.0001909 | 0.006438 |
139 | POST EMBRYONIC DEVELOPMENT | 9 | 89 | 0.0001948 | 0.006522 |
140 | POSITIVE REGULATION OF ORGAN GROWTH | 6 | 38 | 0.0002021 | 0.006716 |
141 | BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE | 11 | 131 | 0.000209 | 0.006898 |
142 | REGULATION OF CELL MATRIX ADHESION | 9 | 90 | 0.0002122 | 0.006953 |
143 | FOREBRAIN DEVELOPMENT | 20 | 357 | 0.000221 | 0.007192 |
144 | ENERGY RESERVE METABOLIC PROCESS | 8 | 72 | 0.0002292 | 0.007405 |
145 | PROTEIN LOCALIZATION TO NUCLEUS | 12 | 156 | 0.0002485 | 0.007976 |
146 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 33 | 750 | 0.0002592 | 0.008261 |
147 | REGULATION OF MAPK CASCADE | 30 | 660 | 0.0002862 | 0.00906 |
148 | RESPONSE TO INORGANIC SUBSTANCE | 24 | 479 | 0.0002896 | 0.009103 |
149 | POSITIVE REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION DEPENDENT DECAY | 4 | 15 | 0.0002981 | 0.009166 |
150 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 32 | 724 | 0.0002964 | 0.009166 |
151 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 14 | 207 | 0.0002994 | 0.009166 |
152 | REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION DEPENDENT DECAY | 4 | 15 | 0.0002981 | 0.009166 |
153 | SKELETAL MUSCLE ORGAN DEVELOPMENT | 11 | 137 | 0.0003088 | 0.009392 |
154 | POSITIVE REGULATION OF HEART GROWTH | 5 | 27 | 0.0003214 | 0.009711 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | PROTEIN KINASE ACTIVITY | 41 | 640 | 2.872e-09 | 9.91e-07 |
2 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 61 | 1199 | 3.2e-09 | 9.91e-07 |
3 | ENZYME BINDING | 79 | 1737 | 2.047e-09 | 9.91e-07 |
4 | KINASE ACTIVITY | 47 | 842 | 1.52e-08 | 3.53e-06 |
5 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 51 | 992 | 5.124e-08 | 9.519e-06 |
6 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 30 | 445 | 1.382e-07 | 2.139e-05 |
7 | TRANSMEMBRANE RECEPTOR PROTEIN KINASE ACTIVITY | 12 | 81 | 2.91e-07 | 3.861e-05 |
8 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 36 | 629 | 4.445e-07 | 5.162e-05 |
9 | PROTEIN DOMAIN SPECIFIC BINDING | 35 | 624 | 1.028e-06 | 0.0001061 |
10 | KINASE BINDING | 33 | 606 | 3.966e-06 | 0.0003685 |
11 | GROWTH FACTOR BINDING | 13 | 123 | 4.782e-06 | 0.0004039 |
12 | PDZ DOMAIN BINDING | 11 | 90 | 6.317e-06 | 0.0004891 |
13 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 22 | 328 | 7.107e-06 | 0.0005079 |
14 | UBIQUITIN LIKE PROTEIN TRANSFERASE ACTIVITY | 24 | 420 | 3.908e-05 | 0.002594 |
15 | SEQUENCE SPECIFIC DNA BINDING | 44 | 1037 | 5.749e-05 | 0.00356 |
16 | TRANSLATION REPRESSOR ACTIVITY | 5 | 20 | 7.041e-05 | 0.004088 |
17 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE ACTIVITY | 8 | 64 | 9.932e-05 | 0.005428 |
18 | ADENYL NUCLEOTIDE BINDING | 57 | 1514 | 0.0001261 | 0.006506 |
19 | REGULATORY REGION NUCLEIC ACID BINDING | 36 | 818 | 0.000136 | 0.006652 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | PML BODY | 12 | 97 | 2.11e-06 | 0.001232 |
2 | SYNAPSE | 35 | 754 | 5.959e-05 | 0.009911 |
3 | RECEPTOR COMPLEX | 20 | 327 | 6.788e-05 | 0.009911 |
4 | PLASMA MEMBRANE REGION | 41 | 929 | 4.366e-05 | 0.009911 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 13 | 139 | 1.823e-05 | 0.000948 | |
2 | FoxO_signaling_pathway_hsa04068 | 12 | 132 | 5.04e-05 | 0.001036 | |
3 | PI3K_Akt_signaling_pathway_hsa04151 | 21 | 352 | 6.42e-05 | 0.001036 | |
4 | Cellular_senescence_hsa04218 | 13 | 160 | 7.972e-05 | 0.001036 | |
5 | MAPK_signaling_pathway_hsa04010 | 18 | 295 | 0.0001598 | 0.001662 | |
6 | cGMP_PKG_signaling_pathway_hsa04022 | 11 | 163 | 0.00132 | 0.01144 | |
7 | Ras_signaling_pathway_hsa04014 | 13 | 232 | 0.002686 | 0.01651 | |
8 | Rap1_signaling_pathway_hsa04015 | 12 | 206 | 0.002817 | 0.01651 | |
9 | Hippo_signaling_pathway_hsa04390 | 10 | 154 | 0.002857 | 0.01651 | |
10 | Jak_STAT_signaling_pathway_hsa04630 | 10 | 162 | 0.004102 | 0.02133 | |
11 | p53_signaling_pathway_hsa04115 | 6 | 68 | 0.004516 | 0.02135 | |
12 | Sphingolipid_signaling_pathway_hsa04071 | 8 | 118 | 0.005665 | 0.02455 | |
13 | HIF_1_signaling_pathway_hsa04066 | 7 | 100 | 0.007948 | 0.03129 | |
14 | Regulation_of_actin_cytoskeleton_hsa04810 | 11 | 208 | 0.008425 | 0.03129 | |
15 | Apelin_signaling_pathway_hsa04371 | 8 | 137 | 0.01337 | 0.04635 | |
16 | Gap_junction_hsa04540 | 6 | 88 | 0.01533 | 0.04969 | |
17 | Focal_adhesion_hsa04510 | 10 | 199 | 0.01625 | 0.04969 | |
18 | Phosphatidylinositol_signaling_system_hsa04070 | 6 | 99 | 0.02579 | 0.07451 | |
19 | TGF_beta_signaling_pathway_hsa04350 | 5 | 84 | 0.04299 | 0.1166 | |
20 | ErbB_signaling_pathway_hsa04012 | 5 | 85 | 0.04486 | 0.1166 | |
21 | Phospholipase_D_signaling_pathway_hsa04072 | 7 | 146 | 0.05016 | 0.1186 | |
22 | Wnt_signaling_pathway_hsa04310 | 7 | 146 | 0.05016 | 0.1186 | |
23 | mTOR_signaling_pathway_hsa04150 | 7 | 151 | 0.05808 | 0.1313 | |
24 | Adherens_junction_hsa04520 | 4 | 72 | 0.08205 | 0.1778 | |
25 | Hedgehog_signaling_pathway_hsa04340 | 3 | 47 | 0.09159 | 0.1905 | |
26 | Notch_signaling_pathway_hsa04330 | 3 | 48 | 0.09612 | 0.1922 | |
27 | TNF_signaling_pathway_hsa04668 | 5 | 108 | 0.101 | 0.1945 | |
28 | ECM_receptor_interaction_hsa04512 | 4 | 82 | 0.1175 | 0.2183 | |
29 | Calcium_signaling_pathway_hsa04020 | 7 | 182 | 0.1235 | 0.2214 | |
30 | Hippo_signaling_pathway_multiple_species_hsa04392 | 2 | 29 | 0.141 | 0.2444 | |
31 | VEGF_signaling_pathway_hsa04370 | 3 | 59 | 0.1514 | 0.25 | |
32 | Cell_cycle_hsa04110 | 5 | 124 | 0.1538 | 0.25 | |
33 | Cytokine_cytokine_receptor_interaction_hsa04060 | 9 | 270 | 0.1656 | 0.2551 | |
34 | Autophagy_animal_hsa04140 | 5 | 128 | 0.1686 | 0.2551 | |
35 | NF_kappa_B_signaling_pathway_hsa04064 | 4 | 95 | 0.1717 | 0.2551 | |
36 | Tight_junction_hsa04530 | 6 | 170 | 0.1931 | 0.2743 | |
37 | Endocytosis_hsa04144 | 8 | 244 | 0.1952 | 0.2743 | |
38 | ABC_transporters_hsa02010 | 2 | 45 | 0.2739 | 0.3748 | |
39 | cAMP_signaling_pathway_hsa04024 | 6 | 198 | 0.2981 | 0.3975 | |
40 | Oocyte_meiosis_hsa04114 | 4 | 124 | 0.3135 | 0.4076 | |
41 | Apoptosis_hsa04210 | 4 | 138 | 0.386 | 0.4896 | |
42 | AMPK_signaling_pathway_hsa04152 | 3 | 121 | 0.5233 | 0.6447 | |
43 | Peroxisome_hsa04146 | 2 | 83 | 0.5675 | 0.6707 | |
44 | Cell_adhesion_molecules_.CAMs._hsa04514 | 3 | 145 | 0.6457 | 0.7462 | |
45 | Phagosome_hsa04145 | 3 | 152 | 0.677 | 0.7653 | |
46 | Necroptosis_hsa04217 | 3 | 164 | 0.7257 | 0.8029 | |
47 | Lysosome_hsa04142 | 2 | 123 | 0.7741 | 0.8248 | |
48 | Neuroactive_ligand_receptor_interaction_hsa04080 | 3 | 278 | 0.9543 | 0.9925 |